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Based on the knowledge thnt expression of the cystic fibrosis trnnsmcmbrane conductance regulator (CFTR) gene can be modulated at the 
transcriptional level, nnd that the CFTR gcnc promoter contains sequences homologous to elements in other promoters that respond to tumor 
necrosis factor-a (TNF), we cvnluatcd the hypothesis that TNF might modulate CFTR gene expression in cpithelial cells. Studies with HT.29 cells, 
;I colon epithclium-derived tumor cell line known to express the CFTR gene, demonstrated that TNF dovvnreguluted CFTR mRNA transcript 
levels in a dose- and time-dependent fashion. Interestingly, nuclear un-on analyses demonstrated that TNF did not uffect the rate oF transcription 
ofCFTR gene, but exposure of the cells to TNF did modify the stability orCFTR mRNA transcripts, resulting in a mRNA half-life that was reduced 
to G5% OF the resting level. These observations uggest hnt CFTR gene expression can be modulated by TNF, at least in part, at the post- 
transcriptional level. 
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1. INTRODUCTION 
Cystic fibrosis (CF), a fatal recessive hereditary disor- 
der characterized by abnormalities of electrolyte tranr- 
port in organs such as the lungs, sweat glands, pancreas 
and intestines, results from mutations of the cystic fi- 
brosis transmembrane conductance regulator (CFTR) 
gene [l-4]. Several lines of evidence suggest that the 
CFTR gene product is a cyclic AMP-regulated Cl’ 
channel on the apical surface of epithelial cells [5-l 11. 
Although the link between mutations of CFTR gene 
and the pathogenesis of CF is not completely defined, 
the available evidence supports the concept that it is 
expression of the abnormal CFTR gene in the epithelial 
cells of affected organs that leads to the profound clin- 
ical manifestations of CF [l-l 11. 
There is a growing body of evidence that expression 
of the CFTR gene is rcgulatable. Although the 5’-flank- 
ing region of cxon 1 of the CFTR gene has the charac- 
teristics of a housekeeping ene, it contains a number 
of known putative regulatory sequences [12,13]. Fur- 
ther, phorbol esters [l&14] and agents that mobilize 
intracellular calcium [ 151 downregulate CFTR gene ex- 
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pression at the level of transcription, resulting in de- 
creased CFTR mRNA transcript levels. 
In the present study, we evaluated the ability of tumor 
necrosis factor-a (TNF) to modulate the expression of 
the CFTR gene in epithelial cells. WC choose TNF as 
a ‘model’ stimulus based on the recognition that the 
5’“flanking region of CFTR gene includes a 28 bp se- 
quence that shows an 89% homology with a sequence 
within the promoter of the human al(I) collagen gene 
[16], and that TNF downregulates the rate of al(I) col- 
lagen gene transcription [17]. Surprisingly, although the 
data demonstrate that TNF downregulates CFTR gene 
expression, it does not influence transcription, but does 
affect CFTR mRNA stability. 
2. MATERIALS AND METHODS 
2.1. Cell c~rltirre 
The HT.23 colon cpithelium-derived adenocarcinorna cell line 
(American Type Culture Collection [ATCC], HTB 38) is known to 
express both the CFTR gene and the TNF receptor gene [ 12,151. Cells 
were maintained in Dulbccco’s modified Eagle medium (DMEM, 
Whittaker Bioproducts) supplcmcnkd with 10% fetal bovine serum 
(FBS), 2 mM glutamine, 50 U/ml penicillin and TO,@ml strsptomycin 
(all from Biofluids). In the studies to investigalc the modulation of 
CFTR gene expression by TNF, experiments were cirrriLd out in both 
serum supplemented and serum-free conditions. HT-29 monolayers 
were washed with medium, incubated For I2 h, 37OC under the same 
conditions, and then incubated alone or with human recombinant 
TNF (20 Wng, Gcnzymc) for specitied times end doses. The cells were 
then b;trvestLti ior cvaiuntiou (arc b&w). No diiTerences were ob- 
scrvcd in serum-supplemented or serum-free conditions nnd thus all 
data shown arc derived l’rom the serum-free conditions. 
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2.2. Ewhwion of CFrR mRNA rraascripls 
The levels of CFTR mRNA transcripts and, 3s B endogenous con- 
trol,@-actin mRNA transcripts, weredetcrmind by Northern analysis 
[ 191. Total cellular RNA was isolated by the guanidine thiocyanatem 
CsCl gradient method [20], RNA (I S,ug/lanc) was subjected to formal- 
dehyde-agarose g l electrophoresis, transferred to a nylon membrane 
(Nytran, Schlcichcr and Schuell), hybridized with a ‘*P&bclcd CFTR 
or /3mnctin cDNA probe generated by the random priming method 
121,221, and evaltinted by auloradiography. The CFTR cDNA probe 
(pTG4964) was prepared as previously described [14]. The cDNA 
clone pHFpA-I was used for the /3-actin probe [23]. 
2.3. Mohlu~to~~ of CFTR gene exprrsslon in NT-28 cells by TNF 
To evaluate the dose-dependency of TNF-induced modulation of 
CFTR gene expression, HT-29 cells were exposed to various concen- 
trations olTNF (O-100 n&ml) for 8 h. To determine the timedepend- 
ency or CFTR gene expression, cells were incubated for various times 
(O-24 h) in the presence ofTNF at the final concentration of 10 @ml. 
Following the incubations, tolal cellular RNA was isolated, and the 
levels of CFTR and, as u endogcnous control, /Y-actin mRNA tran- 
scripts were evaluated by Northern analysis as described above. The 
autoradiographic signals were quantified using a luser densitometer 
(Ultroscan Laser Densitometer, Phormacia LKIS). In the dosc-dc- 
pcndent study, CFTR nnd p-actin mRNA transcript levels were ex- 
pressed as percent of the unstimulated level defined as 100%. In the 
time-course study, CFTR mRNA transcript levels in the absence 01 
presence of TNF were exprcssecl as percent of the lcvcl at time zero 
defined as 100%. 
The rate of CmR gene transcription was examined by nuclear 
transcription run-on analysis [I 2.211. Nuclei were isolated from 5 x IO’ 
rcsling or TNF-stimulated (IO ng/ml; 4 and 8 h) cells, and incubated 
(20 min, 37’C) with 5 mM ATP, 2 mM CTP, 2 mM UTP, 250,Ki 
[a-‘?P]GTP (* 400 Cilmmol; Amcrsham) and 700 U/ml RNase inhib- 
itor (RNasin, Promega) to label actively transcribed RNA. RNA wds 
recovered by the acid guanidinium thiocyanote-phenol-chloroform 
method [24], purified by Scphadex G-50 column chromalography (5 
Prime+3 Prime) and hybridized to excess amounts (5 pg) of DNA 
targets (see below) immobilized on Nytrnn [12,21]. The membranes 
were then washed, exposed to RNase A (5 pg/ml) and RNase T, (5 
U/ml). followed by protcinase K (50 ,ugfml) (all from Boehringer 
Manabcim Biochemicals), and evaluated by autoradiography. The 
DNA targets included plasmids ontaining a CFTR cDNA 
(pTCi49G4), a human p-actin cDNA (pHFPA-I), or, as a negative 
control, the plasmid pBlueskript II SK+ (PBS, Stratagene) containing 
no human DNA. Interleukin63 (lL-8) cDNA (pPB248) w3s used as a 
positive control for TNF stimulation (the rate oflL-8 gene transcrip- 
tion is upregulated by TNF in epithelial cells [25]). To determine the 
relative rate of CFfR gene transcription after TNF stimulation com- 
pared lo the resling rate, the autoradiograms were quantified using a 
laser densitometer, expressed as% of the transcription rate of /3-actin 
endogenous control (defmed as 100%) and the values normalized to 
relative length of the mRNA coding sequences within DNA targels 
(CFfR 4.5 kb; p-actin 2.0 kb, respectively). 
To cvaluatc the stability of CFfR mRNA transcripts, HT-29 cells 
at rest and after incubation with TNF (10 ndml; 8 h) were exposed 
ta nctinomycin D (5 &ml. US Biochemicals) for 0 to 24 h to block 
further transcription, In three separate experiments, total cellular 
RNA wns extracted, CFTR mRNA levels were evaluated by Northern 
analysis as described above, and quantilicd by laser densitometry. 
3. RESULTS 
3.2. Moclttlarion of CFTA &WA levels by TNF 
Northern analyses demonstrated that the HT-29 
colon carcinoma cell line expressed 6.5 kb CFTR 
mRNA transcripts, but the CFTR transcript level de- 
creased markedly after exposure to TNF (Fig. 1; lanes 
fbactin 
Rest + TNF Rest + TNF 
1 2 
Fig. 1. Modulation of CFTR mRNA levels by TNF in l-IT-29 epithc- 
lial cells. Shown are Northern analyses of RNA (15 &lane) from 
reeling cells and cells exposed to TNF (IO ndml, Sh) hybridized with 
“2P-labelsd CFfR (lanes I and 2) or /3-actin probes (lanes 3 and 4). 
The sizes of mRNA transcripts arc indicated. 
1,2). In contrast, the level of p-actin mRNA transcripts 
was similar in amount in resting cells and cells exposed 
to TNF (lanes 3,4). 
TNF exposure decreased the levels of CFTR mRNA 
transcripts in a dose-and time-dependent fashion (Fig. 
2). TNF-induced downregulation of CF‘TR gene ex- 
pression was observed at very low concentrations of 
TNF (0.1 q/ml) and the CFTR transcript level was 
further decreased with increasing concentrations of 
TNF up to 100 ngfml. In contrast, the ievrl of j%actin 
mRNA transcripts in the same cells did not change 
significantly with the dose of TNF. With a fixed dose 
of TNF (10 r&ml), CFTR mRNA transcript levels de- 
clined over time with a minimum at 8 h. By 12 h, the 
levels had increased, but still remained below the levels 
of the resting cells at 24 h. In contrast, resting HT-29 
cells had mildly increasing levels of CFTR mRNA tran- 
scripts throughout the same period. This data was con- 
firxzed with two additional experiments. 
3.2. Effects of TNF on the rate of trartscriptiort of the 
CFTR gene 
Isolated nuclei from resting HT-29 cells demon- 
strated a low rate of transcription of the CFTR gene 
(Fig. 3). Interestingly, at 4 and 8 h following TNF expo- 
sure, the rate of CFTR gene transcription did not 
change compared to the resting rate (Fig. 3 for 8 h data; 
4 h data not shown). The transcription rate of the /% 
actin gene also did not change with TNF. The relative 
transcription rate of the CFTR gene compared to that 
of the p^-aciia gc11e w&s 
. 
! 1% +s:tr;g: ;;z:u . ” ,Y , . . . . rl lfh~Z% lTNF 
Sh). In contrast, the rate of the transcription of the IL-8 
gene was dramatically increased after TNF stimulation. 
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Fig. 2. CFTR mRNA levels in MT-29 cells following exposure to TNF. A. CFTR (0) and fl-nctin (0) mRNA transc:;ipt levels in response to 
increasing concentrations of TNF (O-100 @ml, 8h). B. Time course of CFTR mRNA cxprcssion in resting l-lT-29 cells (0) or cells exposed to 
TNF (IO ngfml) for various periods of time (0). The data rcprescnt densitometric scanning of the autoradiograms of Northern analyses, and each 
data point is presented as % of the resting lcvcl (A) and level at time zero (8) resprrctively (defined as 100%). Shown are representative data from 
two scparnte xperiments. 
3.3. Sttrbility of CFTR mRNA transcripts 
Following inhibition of RNA synthesis with actino- 
mycin D, CFTR mRNA levels in resting HT-29 cells fell 
relatively slowly with a half-life of 18.7 11, suggesting 
that CFTR mRNA transcripts were relatively stable in 
the resting state (Fig. 4). In contrast, the addition of 
TNF to MT-29 ceils decreased the half-life of the CFTR 
mRNA transcripts (12.2 h), suggesting that downregu- 
lation of CFTR transcript levels following TNF stimu- 
lation is modulated, at least in part, by changes in tran- 
script stability. Three separate xperiments were carried 
out to conlirm these results. 
4. DISCUSSION 
The critical role of the CFTR gene product in many 
tissues with epithelial surfaces is highlighted by the pro- 
found clinical manifestations of cystic fibrosis in the 
gastrointestinal and respiratory tracts [l]. The CFTR 
gene is expressed at low levels in these sites, as evidenced 
by the low abundance of CFTR mRNA in epithelial 
cells exainined [3,12,26!. There is evidence, however, 
that expression of the CFTR gene can be modulated by 
mediators such as phorbol esters [12,14] and calcium 
ionophores [15], and by the state of differentiation and/ 
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or proliferation state of the cell [27,28]. In those exam- 
ples where the level of modulation has been identified, 
control of CFTR expression appears to be focused at 
.the level of transcription [12,15]. Consistent with these 
observations, analysis of the promoter of the CFTR 
gene shows it has a variety of putative control sequences 
capable of binding regulatory proteins, despite its over- 
all characteristics as a housekeeping-type gene and its 
relatively low level of expression in epithelial cells [12]. 
The concept that TNF might modulate CFTR 
mRNA levels arose from the recognition that a segment 
of the CFTR promoter (-168 to -141 from the major 
CFTR transcription start site in T84 and MT-29 colon 
carcinoma cells) had an 89% homology with a sequence 
of the al(I) collagen gene promoter that responds to 
TNF by downregulating the rate of gene transcription, 
although the direct linkage between the sequence and 
modulation by TNF is unknown [12,16,17]. Together, 
the knowledge that TNF is produced by inflammatory 
cells frequently populating epithelial surface in CF [29- 
36], and the observation of elevated TNF levels in 
plasma and respiratory epithelial ining fluid of individ- 
uals with CF [37,38] leads to the hypothesis that TNF 
may play a role in modulating CFTR gene expression. 
Interestingly, the data demonstrates that although 





Fig. 3. Ef%ct of TNF on the transcription rate of the CFTR gene in 
MT-29 cells. The cells were incubated in the abscncc or prcscncc of 
TNF (10 n&nl) for 8 h. “P-1abcled nascent nuclear RNA was hybrid- 
ized to nylon membrane-bound DNA plasmid targets (5 pg each) 
including CFTR cDNA, fl-actin cDNA, pBlucscript II SK+ (pDS. an 
irrelevant plasmid control) and IL-S cDNA. Shown is an nuloradi- 
ogram rupmscntativc of three individual experiments. Lane I, Resting 
MT-29 CCIIS; lane 2, l-IT-29 cells after TNF exposure. Note that no 
significant change was obscrvbti n trnnscription levels of the CFTR 
gene as well as endogenous control fi-actin gene after incubation with 
TNF, while 1L-8 gcnc transcription increased markedly. 
TNF causes CFTR mRNA levels to decline in epithelial 
cells, it does so, at least in part, by reducing the half-life 
of CFTR mRNA transcripts, not by suppressing the 
rate of transcription of the CFTR gene. However, since 
CFTR mRNA levels are profoundly suppressed as soon 
as 4. h after exposure and the overall decrease in CFTR 
mRNA transcript levels surpass the decrease in the 
mRNA half-life, it is likely that other mechanism(s), 
such as processing of heterogenous nuclear RNA fol- 
lowing transcription of the CFTR gene in nuclei result- 
ing in instability, or different unstable population of 
CFTR mRNA transcripts in the presence of TNF, con- 
tribute to the TNF-induced down regulation of CFTR 
gene expression. Of genes known to be regulated by 
TNF, the modulation occurs primarily at the transcrip- 
tional level [34,35]. Post-transcriptional modulation by 
TNF has been observed for the gene for macrophage- 
specific colony stimulating factor, but unlike CFTR, 
this gene is also modulated by TNF at the transcrip- 
tional level [39]. 
The fact that TNF can modulate CFTR gene expres- 
sion at the post-transcriptional level has implications 
for designs for the gene therapy of CF. Based on the 
evidence that the human CFTR gene can be transferred 
the epithelia of the lung in vivo, it is now possible to 
conceptualize such an approach [40]. One of the impor- 
tant questions in designing gene therapy for CF is 
whether or not the transferred gene will have to be 
controlled at the transcriptional level. Likely, this ques- 
tion will have to be answered empirically, but the deci- 
sion to include regulatory elements will partly depend 
on the list of known modulators of the CFTR gene, and 
their theoretical relevance for in viva modulation of the 
gene. In the context that TNF is present in elevated 
levels in the plasma and respiratory epithelial lining 
fluid of individuals with CF [37,38], the fact that TNF 
regulates CFTR mRNA levels at the post-transcrip 
tional level suggests that concerns about transcriptional 
control (at least for this mediator) are irrelevant for 
gene therapy, as long as the normal CFTR gene that is 
transferred has the appropriate (as yet unknown) recap 
nition sequences for TNF to modulate CFTR mRNA 
stability [41]. 
As regards to cystic fibrosis, theoretically, TNF could 
play a modulating influence on the disease state. In this 
regard, there is anecdotal evidence that compound ‘null’ 
heterozygotes with stop codon mutations of CFTR pro- 
tein coding sequence have milder lung disease than do 
individuals homozygous for the common dF508 muta- 
tion [42]. Thus, it is conceivable that downregulation of 
expression of the CFTR gene in dF508 homozygotes 
may have a moderating influence in the disease, i.e. by 
converting the AFT08 homozygous tate to the equiva- 
lent of the homozygous null state. 
Finally, the fact that TNF can modulate the expres- 
sion of the normal CFT’R gene has implications for the 
modulation of this gene by inflammatory mediators in 












Resting (T/2 18.7 h) 
” 
0 4 8 12 18 20 24 
Time after addition st actinomycin D (h) 
Fig. 4. Change in stability of CFTR mRNA transcripts in l-IT-29 cells 
in response to TN F. Shown nre ctl&ts of inhibition of RNA synthesis 
on CFTR mKNA levels in resting (0) or TNF-treated (10 @ml, 8 h) 
LfT-29 ceils (G). CC% wcrc ktvcstcd 2:: the indicted timr~ after the 
addition of actinomycin D (5 yg/ml) and extracted RNA was evnlu- 
ated by Northern analysis. Dsta shown arc representative of three 
individual experiments. 
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released by activated macrophages and neutrophils, 
cells commonly associated with epitheiial inflammation 
[29-361. In this regard, it is conceivable that local 
downregulation of the CFTR gene, and induces ‘local- 
ized cystic fibrosis’ in the affected region, i.e. inflamma- 
tion on the surface of epithelial cells may signal 
downregulation of the CFTR gene, with the consequent 
equivalent of a mild cystic fibrosis phenotype in the 
local milieu. 
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